

Burden of Typhoid in Cambodia

Cambodia is a typhoid-endemic country. The Global Burden of Disease study estimated that, in 2023, there were at least:

- 9,319 typhoid cases** (54 cases per 100,000)
- 104 typhoid deaths**
- 7,719 disability-adjusted life-years lost** to typhoid¹


While typhoid is rarely fatal, the recovery is long and difficult. The disease takes time, money, and productivity from those infected and their families and is associated with numerous long-term complications.



Most typhoid cases in Cambodia occur in children younger than 15 years old.



TYPHOID CASES IN CAMBODIA BY AGE (2023)



Drug-resistant typhoid strains are a growing problem in Cambodia, regionally, and across the globe.



Global data show that the multidrug-resistant (MDR) H58 typhoid strain prevalence has **increased dramatically since 1992**.²



A study found that **typhoid in Cambodian children is dominated by the H58 strain**. Additionally, 85% of the isolates analyzed were MDR, leading the authors to conclude that drug-resistant typhoid is common in Cambodian children and therapeutic options are limited.³



Another study found that the majority of isolates tested were MDR, and 80% had reduced susceptibility to ciprofloxacin⁴, the standard treatment for typhoid in many parts of the world.



As drug-resistant typhoid becomes more common, it will become more difficult to treat and **force the use of more expensive and less readily-available** treatment options.

Typhoid conjugate vaccines (TCVs) in Cambodia

The World Health Organization (WHO) recommends the introduction of prequalified TCVs be prioritized in countries with a high burden of typhoid disease or a high burden of drug-resistant typhoid. Gavi, the Vaccine Alliance support for introduction is available now. TCVs:



Are highly effective and safe for children as young as **6 months** of age;



Require a **single dose** to prevent 79-85% of typhoid cases in children;^{5,6}



Offer strong protection for **at least 4 years**; and



Can be **co-administered with measles-rubella** vaccine.⁷

Findings from an economic analysis predict that, even in the absence of a Gavi subsidy, a catch-up campaign with TCV could be cost-effective in Cambodia.⁸

Let's Take on Typhoid in Cambodia

- ✓ Typhoid is endemic in Cambodia, with more than **9,300** cases per year.
- ✓ Cambodia's typhoid burden is most heavily borne by children **younger than 15** years old.
- ✓ Data show an increase in **drug-resistant typhoid** in Cambodia and globally.
- ✓ **TCVs** are safe, effective, and WHO-recommended for routine immunization as part of a cost-effective, integrated approach to typhoid prevention and control alongside safe water, sanitation, and hygiene interventions.
- ✓ **Gavi support** for TCV introduction is available **now**.

1. Institute for Health Metrics and Evaluation. Global Burden of Disease. 2023. Accessed via: ghdx.healthdata.org/gbd-results-tool.
2. Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella* Typhi identifies inter- and intracontinental transmission events. *Nature Genetics*. 2015;47(6):632-639.
3. Emary K, Moore CE, Chanpheaktra N, et al. Enteric fever in Cambodian children is dominated by multidrug-resistant H58 *Salmonella enterica* serovar Typhi with intermediate susceptibility to ciprofloxacin. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2012;106(12):718-724.
4. Kasper M, Sokhal B, Blair PJ, et al. Emergence of multidrug-resistant *Salmonella enterica* serovar Typhi with reduced susceptibility to fluoroquinolones in Cambodia. *Diagnostic Microbiology and Infectious Disease*. 2010;66(2):207-209.
5. Shakya M, Voysey M, Theiss-Nyland K, et al. Efficacy of typhoid conjugate vaccine in Nepal: Final results of a phase 3, randomised, controlled trial. *The Lancet Global Health*. 2021;9(11):e1561-1568.
6. Qadri F, Khanam F, Liu X, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: A cluster-randomised trial. *The Lancet*. 2021;398(10301):675-684.
7. Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. *International Journal of Infectious Diseases*. 2021;108:465-472.
8. Bilcke J, Antillón M, Pieters Z, et al. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: A modelling study. *Lancet Infectious Disease*. 2019;19(7):728-739.